0001104659-26-059392
SEC filingRezolute, Inc. reported Q3 fiscal 2026 financial results with net loss of $16.2 million, cash position of $120.3 million, and positive Phase 3 sunRIZE study CGM analyses for ersodetug in congenital HI.
Rezolute's Q3 fiscal 2026 results reflect a narrowing net loss to $16.2 million from $18.9 million year-over-year, primarily due to R&D expense reduction to $11.4 million from $15.3 million, attributed to lower manufacturing costs for ersodetug and decreased clinical trial activities. G&A expenses rose to $6.0 million from $4.7 million, driven by higher stock-based compensation, partially offset by lower professional fees. Cash position of $120.3 million provides runway amid ongoing development. The highlight is expanded Phase 3 sunRIZE analyses presented at PES 2026, showing ersodetug's significant CGM-based improvements: >50% reduction in hypoglycemia time, 50-80% fewer events, 25-50% more normoglycemia exposure, and 10-15 mg/dL higher average glucose versus placebo. High open-label extension participation sustains benefits while reducing standard therapies. FDA's March 2026 Type B meeting recognized HI trial challenges with SMBG metrics, encouraging comprehensive data submission for review. For tumor HI, upLIFT Phase 3 enrollment advances toward H2 2026 topline data, building on prior EAP outcomes. These clinical advancements position ersodetug for potential regulatory progress in congenital and tumor HI, core to Rezolute's rare disease focus.